Business Description
Gyre Therapeutics Inc
NAICS : 541714
SIC : 2833
ISIN : US4037831033
Total Employee Number:
618Description
Gyre Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 21.88 | |||||
Equity-to-Asset | 0.54 | |||||
Debt-to-Equity | 0.03 | |||||
Debt-to-EBITDA | -0.33 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 1/9 | |||||
Altman Z-Score | 7.42 | |||||
Beneish M-Score | -2.66 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -5.4 | |||||
3-Year EBITDA Growth Rate | 0.2 | |||||
3-Year EPS without NRI Growth Rate | -59.5 | |||||
3-Year Book Growth Rate | 27.9 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 80.51 | |||||
9-Day RSI | 66.18 | |||||
14-Day RSI | 59.11 | |||||
3-1 Month Momentum % | -5.83 | |||||
6-1 Month Momentum % | -14.39 | |||||
12-1 Month Momentum % | -4.24 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 4.26 | |||||
Quick Ratio | 3.86 | |||||
Cash Ratio | 2.61 | |||||
Days Inventory | 543.36 | |||||
Days Sales Outstanding | 80.78 | |||||
Days Payable | 24.15 |
Profitability Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 94.3 | |||||
Operating Margin % | -11.41 | |||||
Net Margin % | -14.58 | |||||
EBITDA Margin % | -8.78 | |||||
FCF Margin % | -6.19 | |||||
OCF Margin % | -4.33 | |||||
ROE % | -17.09 | |||||
ROA % | -10.37 | |||||
ROIC % | -15.02 | |||||
3-Year ROIIC % | 7.67 | |||||
ROC (Joel Greenblatt) % | -29.66 | |||||
ROCE % | -9.2 | |||||
Years of Profitability over Past 10-Year | 4 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 108.33 | |||||
PS Ratio | 5.64 | |||||
PB Ratio | 6.24 | |||||
Price-to-Tangible-Book | 6.46 | |||||
EV-to-EBIT | -48.89 | |||||
EV-to-Forward-EBIT | -28.23 | |||||
EV-to-EBITDA | -63.48 | |||||
EV-to-Forward-EBITDA | -28.23 | |||||
EV-to-Revenue | 5.57 | |||||
EV-to-Forward-Revenue | 6.35 | |||||
EV-to-FCF | -94.25 | |||||
Price-to-GF-Value | 0.73 | |||||
| Price-to-Net-Current-Asset-Value | 21.3 | |||||
Earnings Yield (Greenblatt) % | -2.04 | |||||
FCF Yield % | -1.02 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Gyre Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 102.548 | ||
| EPS (TTM) (€) | -0.181 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 42.87 | ||
| 14-Day RSI | 59.11 | ||
| 14-Day ATR (€) | 0.228966 | ||
| 20-Day SMA (€) | 5.344 | ||
| 12-1 Month Momentum % | -4.24 | ||
| 52-Week Range (€) | 4.68 - 7.7 | ||
| Shares Outstanding (Mil) | 111.49 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Gyre Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Gyre Therapeutics Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-06 | In 86 days | ||
| Second quarter earnings results for 2026 | 2026-08-07 | 5.55 (+2.78%) | ||
| General meeting for 2026 | 2026-06-10 10:00 | 5.30 (+1.92%) | ||
| First quarter earnings results for 2026 | 2026-05-07 | 6.80 (+3.03%) | ||
| Annual report for 2025 | 2026-03-13 | 6.70 (-6.94%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-12 | 7.10 (+2.16%) | ||
| Third quarter earnings results for 2025 | 2025-11-07 | 6.30 (+0.80%) | ||
| H.C. Wainwright 27th Annual Global Investment Conference | 2025-09-10 12:30 | 6.45 (-1.53%) | ||
| Second quarter earnings results for 2025 | 2025-08-11 | 6.00 (-0.83%) | ||
| General meeting for 2025 | 2025-06-04 10:00 | 6.55 (+0.00%) |
Show
Entries
Gyre Therapeutics Inc Frequently Asked Questions
What is Gyre Therapeutics Inc(STU:L9S)'s stock price today?
The current price of STU:L9S is €5.75. The 52 week high of STU:L9S is €7.70 and 52 week low is €4.68.
When is next earnings date of Gyre Therapeutics Inc(STU:L9S)?
The next earnings date of Gyre Therapeutics Inc(STU:L9S) is 2026-11-06 Est..
Does Gyre Therapeutics Inc(STU:L9S) pay dividends? If so, how much?
Gyre Therapeutics Inc(STU:L9S) does not pay dividend.
Press Release
Articles on Gyre Therapeutics Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers